Clinical trialCLINICALTRIALSApr 15
Researchers are testing a cancer drug called nivolumab in patients with rare tumors that have a specific marker called PD-L1. This is a Phase 2 trial that will include up to 28 patients with many different types of rare cancers who haven't responded well to standard treatments. The study will last up to 12 months and measure how well the drug works.
WHY IT MATTERSIf you have one of the 43 rare tumor types listed and your cancer has high PD-L1 expression, this trial offers access to an immunotherapy that may work regardless of where your cancer started.
Clinical trialUNITERAREApr 3
Researchers are testing a new experimental drug called KST-6051 in patients with advanced solid tumors (cancers that form in organs or tissues) that have a specific genetic mutation called KRAS. This is an early-stage study (Phase 1) that will test different doses of the drug to find the safest and most effective amount. The trial is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers patients with KRAS-mutated solid tumors access to a novel targeted therapy before it becomes widely available, potentially providing a treatment option for cancers that are often difficult to treat.
Clinical trialCLINICALTRIALSApr 1
Researchers are testing a combination of two cancer drugs called dabrafenib and trametinib in patients with rare tumors that have a specific genetic change called BRAF V600E. This is a phase IV study, which means the drugs have already been approved and doctors are gathering more information about how well they work. The study will include children (age 1 and up) and adults, and is currently looking for 40 patients to participate.
WHY IT MATTERSIf you have a rare solid tumor with a BRAF V600E mutation and your doctor has already recommended dabrafenib plus trametinib treatment, this trial offers an opportunity to participate in research that could help future patients while receiving the same treatment your doctor planned for you anyway.
Clinical trialCLINICALTRIALSMar 26
Researchers at Emory University are testing a new combination of medicines for children whose cancer has come back or stopped responding to previous treatments. The study combines three drugs: sirolimus (which slows cell growth), celecoxib (an anti-inflammatory), and two chemotherapy drugs given in low doses. The goal is to see if this combination works better than standard treatments for solid tumors and brain cancers in children.
WHY IT MATTERSThis trial offers a potential new treatment option for children with recurrent or refractory cancers who have limited alternatives, though enrollment is currently closed.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new experimental cancer treatment called BNT326 to see if it is safe and works well for people with advanced solid tumors (cancers that have spread or come back after treatment). The study will first test BNT326 alone, then test it combined with other experimental treatments. About 980 people will participate in this Phase 1 and Phase 2 trial.
WHY IT MATTERSThis trial is actively recruiting patients with advanced solid tumors across multiple sites, offering access to a novel immunotherapy approach from BioNTech before it becomes widely available.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing whether two cancer-fighting drugs called atezolizumab and bevacizumab work better together for treating rare cancers. These drugs help the body's immune system recognize and attack cancer cells. The study includes 133 patients with various uncommon solid tumors and is currently enrolling participants.
WHY IT MATTERSThis trial offers patients with rare cancers like Merkel cell carcinoma, nasopharyngeal cancer, and mesothelioma access to a combination immunotherapy treatment that may not be available outside of clinical research.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a drug called cabozantinib-s-malate to treat children and young adults with rare cancers, including sarcomas (muscle cancers), Wilms tumor (kidney cancer), and other solid tumors that have come back after treatment or didn't respond to initial therapy. The drug works by blocking proteins that help tumors grow and form new blood vessels. This phase II trial has enrolled 109 patients and is no longer recruiting new participants.
WHY IT MATTERSIf your child has a recurrent or treatment-resistant sarcoma, Wilms tumor, or other rare pediatric solid tumor, this completed trial data may help inform whether cabozantinib could be an option to discuss with their oncologist.